Protech Home Medical to Virtually Attend the Canaccord Genuity 40th Annual Growth Conference on August 11th – 13th
13 Julho 2020 - 9:00AM
Protech Home Medical Corp. (the
“
Company” or “
Protech”)
(TSXV: PTQ) (OTCQX: PTQQF), a U.S. based leader in the home medical
equipment industry, focused on end-to-end respiratory
care, today announced that members of its management team will
be presenting at the upcoming Canaccord Genuity 40th Annual Growth
Conference. The event is being held virtually and will take place
between August 11 to 13, 2020. For more information, please visit
https://www.canaccordgenuity.com/capital-markets/about-us/events/.
Webcasted Presentation
Event: |
Canaccord Genuity 40th Annual Growth Conference |
Date: |
Thursday, August 13, 2020 |
Time: |
8:30am EDT |
The live webcast of the presentation will be
available by visiting the investors' section of the Company's
website at www.protechhomemedical.com. The webcast will also
be available for replay on the Company's website following the
event.
“We are excited to attend this well-known and
prestigious investor conference and have plans to be very active on
the capital markets front including attending U.S. and Canadian
based investor conferences throughout the remainder of 2020,”
commented Greg Crawford, CEO and Chairman of Protech. “On the heels
of our recent financing, which provided us with the strongest
balance sheet in our history, and as we continue to operate at an
extremely high level in the midst of the COVID-19 pandemic, we look
forward to sharing the Protech story with a broader array of
institutional and retail investors.”
ABOUT PROTECH HOME MEDICAL
The Company provides in-home monitoring and
disease management services including end-to-end respiratory
solutions for patients in the United States healthcare market. It
seeks to continue to expand its offerings to include the management
of several chronic disease states focusing on patients with heart
or pulmonary disease, sleep disorders, reduced mobility and other
chronic health conditions. The primary business objective of the
Company is to create shareholder value by offering a broader range
of services to patients in need of in-home monitoring and chronic
disease management. The Company’s organic growth strategy is to
increase annual revenue per patient by offering multiple services
to the same patient, consolidating the patient’s services and
making life easier for the patient.
Forward-Looking Statements
Certain statements contained in this press
release constitute "forward-looking information" as such term is
defined in applicable Canadian securities legislation. The words
"may", "would", "could", "should", "potential", "will", "seek",
"intend", "plan", "anticipate", "believe", "estimate", "expect" and
similar expressions as they relate to the Company, including:
the Company presenting at the event and posting material on its
website; and the Company’s plans to be very active on the capital
markets front including attending U.S. and Canadian based investor
conferences; and are intended to identify forward-looking
information. All statements other than statements of historical
fact may be forward-looking information. Such statements reflect
the Company's current views and intentions with respect to future
events, and current information available to the Company, and are
subject to certain risks, uncertainties and assumptions. Many
factors could cause the actual results, performance or
achievements that may be expressed or implied by such
forward-looking information to vary from those described herein
should one or more of these risks or uncertainties materialize.
Examples of such risk factors include, without limitation: credit;
market (including equity, commodity, foreign exchange and
interest rate); liquidity; operational (including technology and
infrastructure); reputational; insurance; strategic; regulatory;
legal; environmental; capital adequacy; the general business and
economic conditions in the regions in which the Company operates;
the ability of the Company to execute on key priorities,
including the successful completion of acquisitions, business
retention, and strategic plans and to attract, develop and
retain key executives; difficulty integrating newly acquired
businesses; the ability to implement business strategies and
pursue business opportunities; low profit market segments;
disruptions in or attacks (including cyber-attacks) on the
Company's information technology, internet, network access or
other voice or data communications systems or services; the
evolution of various types of fraud or other criminal behavior to
which the Company is exposed; the failure of third parties to
comply with their obligations to the Company or its affiliates;
the impact of new and changes to, or application of, current laws
and regulations; decline of reimbursement rates; dependence on
few payors; possible new drug discoveries; a novel business model;
dependence on key suppliers; granting of permits and licenses in
a highly regulated business; the overall difficult litigation
environment, including in the U.S.; increased competition; changes
in foreign currency rates; increased funding costs and market
volatility due to market illiquidity and competition for funding;
the availability of funds and resources to pursue operations;
critical accounting estimates and changes to accounting standards,
policies, and methods used by the Company; the occurrence of
natural and unnatural catastrophic events and claims resulting
from such events; and risks related to COVID-19 including various
recommendations, orders and measures of governmental
authorities to try to limit the pandemic, including travel
restrictions, border closures, non-essential business closures,
quarantines, self-isolations, shelters-in-place and social
distancing, disruptions to markets, economic activity,
financing, supply chains and sales channels, and a deterioration
of general economic conditions including a possible national
or global recession; as well as those risk factors discussed or
referred to in the Company’s disclosure documents filed with
the securities regulatory authorities in certain provinces of
Canada and available at www.sedar.com. Should any factor affect
the Company in an unexpected manner, or should assumptions
underlying the forward-looking information prove incorrect, the
actual results or events may differ materially from the results
or events predicted. Any such forward-looking information is
expressly qualified in its entirety by this cautionary
statement. Moreover, the Company does not assume responsibility
for the accuracy or completeness of such forward-looking
information. The forward-looking information included in this
press release is made as of the date of this press release and
the Company undertakes no obligation to publicly update or revise
any forward-looking information, other than as required by
applicable law.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information please visit our website
at www.protechhomemedical.com, or contact:
Cole StevensVP of Corporate Development Protech
Home Medical Corp.859-300-6455cole.stevens@myphm.com
Gregory Crawford Chief Executive Officer Protech Home Medical
Corp. 859-300-6455 investorinfo@myphm.com
Protech Home Medical (TSXV:PTQ)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Protech Home Medical (TSXV:PTQ)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025